Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics

Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals

Pfizer and BioNTech granted U.S. EUA for booster dose for kids 5-11 years

Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series

Adroit BioMed launches Fortisil range of skincare products

GeneQuantum Healthcare's two bioconjugate drugs approved for clinical trials in Australia

They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights

Biological E. reduces Corbevax price to Rs.250 a dose

The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12

Neurocrine Biosciences receives Orphan Drug Designation for Valbenazine

The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation

Akston Biosciences doses first participants in Phase II clinical trial for Covid-19 booster

AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022

U.S. Centers for Disease Control and Prevention selects Biobot Analytics to expand national wastewater monitoring

NWSS works with public health departments across the country to track SARS-CoV-2 levels in wastewater so communities can act quickly to prevent the spread of Covid-19.

Lonza, ALSA Ventures collaborate on providing manufacturing services to biotech firms

The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking

Bora Pharmaceuticals acquires Eden Biologics CDMO assets

Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market